Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1779 • ACR Convergence 2024
Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers
Jessica Turnier¹, Chioma Madubata², Christine Goudsmit³, Sean Ferris³, Celine Berthier³, Zilan Zheng⁴, Sophia Matossian³, Jeff Dvergsten⁵, Meredyth Wilkinson⁶, Lucy R Wedderburn⁷, Gabrielle Morgan⁸, Lauren Pachman⁹, Claudia Lalancette³, Stephen Parker³, Andrew Heaton¹⁰, J. Michelle Kahlenberg³, Gabriela K Fragiadakis² and Jessica Neely⁴, ¹University of Michigan, Saline, MI, ²University of California, San Francisco, San Francisco, CA, ³University of Michigan, Ann Arbor, MI, ⁴UCSF, San Francisco, CA, ⁵Duke University Hospital, Hillsborough, NC, ⁶Great Ormond Street Institute of Child Health, London, United Kingdom, ⁷UCL GOS Institute of Child Health, London, United Kingdom, ⁸Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁰Cure JM, Leesburg, VA
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children, and it frequently follows a chronic disease course. Treatments are limited secondary…
Abstract Number: 2161 • ACR Convergence 2024
Parent and Youth Report of Psychosocial Functioning in Chronic Childhood Vasculitis
Camille Wilson¹, Kimberly Morishita², Else Bosman³, Alana Leever⁴, Mahmoud Kallash⁵, Anne Dawson¹, David Cabral⁶ and Vidya Sivaraman⁷, and the PedVas investigator network, ¹Nationwide Children's Hospital, Columbus, OH, ²University of British Columbia - Vancouver, Vancouver, BC, Canada, ³UBC, Vancouver, BC, Canada, ⁴Nationwide Children's Hospital, Ohio State University, Columbus, OH, ⁵Nationwide Children's Hosptial, Columbus, OH, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Nationwide Children's Hospital/ The Ohio State University, Columbus, OH
Background/Purpose: Collaborative research efforts have allowed great strides to advance treatment and care for pediatric patients living with chronic vasculitis. However, little research has been…
Abstract Number: 2195 • ACR Convergence 2024
Pediatric Rheumatology Graduation: A One-Way Bridge to Adult Care?
Kyla Fergason¹, David McDonald¹, Karissa Chesky², Jimin Kim², Tiphanie Vogel¹ and Miriah Gillispie-Taylor³, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: For many patients with childhood onset disease, the transition from pediatric to adult healthcare is difficult, often resulting in lapses in care and increased…
Abstract Number: 2510 • ACR Convergence 2024
The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Francis Lao¹, Cal Robinson², Dorota Borovski³, KAREN BEATTIE⁴, Joycelyne Ewusie⁵, Rahul Chanchlani³ and Michelle Batthish⁶, ¹The Hospital for Sick Children, Hamilton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³McMaster University, Hamilton, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵McMaster University, Hamilton, ⁶McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
Abstract Number: 2653 • ACR Convergence 2024
Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
Elaine Yung¹, Xiaoxuan Liu², Bin Huang³, Michael Wagner¹, Minal Aundhia², Chen Chen⁴ and hermine brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cin, OH, ⁵Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: When uncontrolled, JIA is associated with short-term and long-term complications that affect the patient’s quality of life. A common goal of treatment is to…
Abstract Number: 0384 • ACR Convergence 2024
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Corey J. Bishop¹, Edwin Lam², Sophia G. Liva³, Jocelyn H. Leu², Amy S. Paller⁴, Lucia Z. Diaz⁵, Laura Wine Lee⁶, Cory Rubin⁷, Ruy Carrasco⁸, Lisa Imundo⁹, Azadeh Majlessi¹⁰, Katherine Berezny¹, Kathleen G. Lomax¹, Valerie Smith¹, Renping Zhang¹ and hermine brunner¹¹, ¹Janssen Research & Development, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁵Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, ⁶Medical University of South Carolina, Charleston, SC, ⁷Michigan Dermatology Institute, Waterford, MI, ⁸Pediatric Rheumatology Consultants of Austin, Austin, TX, ⁹Columbia University Medical Center, New York, NY, ¹⁰Newport Huntington Medical Group, Huntington Beach, CA, ¹¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
Abstract Number: 0406 • ACR Convergence 2024
Delayed Diagnosis and Accrual of Joint Damage in Incident Cases of Juvenile Idiopathic Arthritis
Anna Costello¹, Cassandra Muir¹, Rui Xiao², Pamela Weiss³ and Irit Rasooly¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Timely diagnosis of Juvenile Idiopathic Arthritis (JIA) enables early initiation of therapy, prevents accrual of joint damage, and improves outcomes. Data regarding the diagnostic…
Abstract Number: 1068 • ACR Convergence 2024
Improving Health Numeracy Literacy in Pediatric Patients with SLE
Nicole Salach¹, Sarah Rogal¹, Jessica Simpson¹, Sangeeta Sule², Abigail Bosk³ and Catherine Park¹, ¹Children's National Hospital, Washington DC, DC, ²Children's National Hospital, Washington, DC, ³Children's National Hospital, Bethesda, DC
Background/Purpose: Health literacy is key to better patient outcomes. One aspect of health literacy that warrants additional investigation in patients who have systemic lupus erythematosus…
Abstract Number: 1271 • ACR Convergence 2024
Linkage of the Childhood Arthritis and Rheumatology Research Alliance Registry with the Pediatric Health Information System: Creation of a Comprehensive Childhood-Onset Lupus Dataset
Jordan Roberts¹, Anna Faino², Min-Lee Chang³, Jonathan Cogen⁴, Matt Hall⁵ and Esi Morgan¹, and for the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, ⁴Seattle Children’s Hospital, Seattle, WA, ⁵Children’s Hospital Association, Lenexa, KS
Background/Purpose: Currently, no comprehensive national multipayer dataset with inpatient and outpatient data exists for childhood rheumatologic diseases, limiting the ability to study outcomes longitudinally and…
Abstract Number: 1452 • ACR Convergence 2024
Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
Timothy Brandon¹, Rui Xiao², Cassandra Muir¹, Matthew Stoll³, Daniel Lovell⁴, Edward Oberle⁵, Nancy Chauvin⁶, Michael Francavilla⁷, Walter Maksymowych⁸ and Pamela Weiss⁹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶The Imaging Institute @ The Cleveland Clinic, Cleveland, OH, ⁷Department of Radiology, Whiddon College of Medicine, University of South Alabama, Mobile, AL, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…
Abstract Number: 1780 • ACR Convergence 2024
Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus
Laura Lewandowski¹, Linda Hiraki², Christiaan Scott³, Ana Barrera-Vargas⁴, Diana Gómez-Martin⁵, Michael Ombrello⁶, Ivona Aksentijevich⁷, Zuoming deng⁸, Anthony Musolf⁹, Subrata Paul¹⁰, Dan Hupalo¹¹, Clifton Dalgard¹¹, Sarfaraz Hasni¹², Earl Silverman¹³ and Mariana Kaplan¹⁴, ¹NIAMS, NIH, Bethesda, MD, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Pediatric Rheumatology, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Federal District, Mexico, ⁵INCMNSZ, Mexico, Distrito Federal, Mexico, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD, ⁷National Human Genome Research Institute, NIH, Bethesda, MD, ⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁹Computational and Statistical Genomics Branch, NHGRI, NIH, Baltimore, MD, ¹⁰Collaborative Bioinformatics Resource, NIAID, NIH, Bethesda, MD, ¹¹The American Genome Center, Department of Anatomy, Physiology & Genetics, Uniformed Services University, Bethesda, MD, ¹²National Institutes of Health, Bethesda, MD, ¹³Silverman, Toronto, ON, Canada, ¹⁴NIAMS/NIH, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a potentially life-threatening autoimmune disease. Childhood-onset SLE (cSLE) patients have younger disease onset and more severe disease than adults,…
Abstract Number: 2166 • ACR Convergence 2024
Nominal Group Technique to Identify What Adolescents with JIA and Parents of Children with JIA Consider When Making Treatment Change Decisions
Melissa Mannion¹, Livie Timmerman², Emily Smitherman¹, Jeffrey Curtis³ and Ronan O'Beirne¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a life-long disease that often requires escalation of therapy to achieve disease control. The goal of this project was…
Abstract Number: 2196 • ACR Convergence 2024
Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings
Suzanne Li¹, Natalia Vasquez-Canizares², Clare Pain³, Marinka Twilt⁴, Amra Adrovic⁵, Abdulrahman Alrasheed⁶, Simone Appenzeller⁷, ADELE CIVINO⁸, narendra bagri⁹, Patricia Costa Reis¹⁰, Muserref Cucueoglu¹¹, Fatma Dedeoglu¹², samundeeswari Deepak¹³, Jianghong Deng¹⁴, Dalia El-Ghoneimy¹⁵, Ivan Foeldvari¹⁶, Fernando Garcia-Rodriguez¹⁷, Marija Jelusic¹⁸, Ankur Jindal¹⁹, Ozgur Kasapcopur²⁰, Maria Katsicas²¹, Archana Khan²², Raju Khubchandani²³, Meiping Lu²⁴, Hanna Lythgoe²⁵, edoardo marrani²⁶, Giorgia Martini²⁷, Takako Miyamae²⁸, Tomo Nozawa²⁹, Seza Ozen³⁰, Lidia Rutkowska-Sak³¹, Sunil Sampath¹³, Dieneke Schonenberg-Meinema³², Hongmei Song³³, Betul Sozeri³⁴, Hayakazu Sumida³⁵, Maria Teresa Terreri³⁶, Kathryn Torok³⁷, Seyma Turkmen³⁸, Dilara Unal³⁸, Gong Yinv³⁹, Emily Willis²⁵, Rongjun Zheng²⁴ and Brian Feldman⁴⁰, and Pediatric International Consortium for Scleroderma, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, ²Children's Hospital at Montefiore, Bronx, NY, ³Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Alberta Children's Hospital, Calgary, AB, Canada, ⁵Koc University Hospital, Istanbul, Turkey, ⁶King Abdullah Specialized Children Hospital, Riyadh, Saudi Arabia, ⁷Unicamp, Campinas, SP, Brazil, ⁸Pediatric Rheumatology "Vito Fazzi" Hospital LECCE, LECCE, Italy, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Hospital de Santa Maria, Lisbon, Portugal, ¹¹Hacettepe University, Ankara, Turkey, ¹²Boston Children's Hospital, Boston, MA, ¹³THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST, Newcastle upon Tyne, United Kingdom, ¹⁴Beijing Children's Hospital, Beijing, China, ¹⁵Children's Hospital, Ain Shams University, Cairo, Egypt, ¹⁶Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹⁷Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico, ¹⁸University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ¹⁹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²⁰Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ²¹Hospital Garrahan, Buenos Aires, Argentina, ²²SRCC Children's Hospital, Mumbai, India, Mumbai, India, ²³The SRCC Children's Hospital, Mumbai, India, ²⁴Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China (People's Republic), ²⁵Royal Manchester Children's Hospital, Manchester, United Kingdom, ²⁶Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, ²⁷University of Udine University Hospital Santa Maria della Misericordia, Udine, Italy, ²⁸Tokyo Women's Medical University, Tokyo, Japan, ²⁹Yokohama City University, Yokohama, Japan, ³⁰Department of Pediatrics, Hacettepe University, Ankara, Turkey, ³¹National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland, ³²Amsterdam University Medical Center, Amsterdam, Netherlands, ³³Peking Union Medical College Hospital, Beijing, China, ³⁴University of Health Sciences, Istanbul, Turkey, ³⁵The University of Tokyo, Tokyo, Japan, ³⁶UNIFESP, São Paulo, SP, Brazil, ³⁷Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ³⁸University of Health Sciences, Umraniye Training and Research Hospital, Ankara, Turkey, ³⁹Children's Hospital Affiliated to Fudan University, Shanghai, China (People's Republic), ⁴⁰Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite the high morbidity and mortality risk associated with juvenile systemic sclerosis (jSSc), evidence to guide management is limited. No jSSc clinical trials have…
Abstract Number: 2529 • ACR Convergence 2024
Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project
Dori Abel¹, Kirsten Spichiger², Megan Roman², William Baar², Claire O'Malley², Jay Mehta¹, Terri Al'Hadi², Kerry Ferraro³, Denique Butler², Asia Wilson-Sanders², Catherine Lewis², Danielle Dodson⁴ and Jon Burnham¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Although new therapeutics and treat-to-target interventions have improved JIA care, pronounced racial and ethnic outcome disparities persist. At our center, the mean population-level clinical Juvenile…
Abstract Number: PP04 • ACR Convergence 2024
Involving Pediatric Patients in Their Own Care
Whitney LaBar, Lupus and Allied Diseases Association, Pleasanton, CA
Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].